Two novel antibiotic candidates for gonorrhea received funding to advance into clinical trials.
Starting in August, eligible patients can receive shots of 4CMenB, a vaccine for meningococcal B disease that provides moderate cross-protection against gonorrhea.
Two systematic reviews and meta-analyses found evidence that OMV-based meningococcal B vaccines offer moderate cross-protection.
A study at a sexual health clinic finds that significant declines in chlamydia and syphilis were sustained nearly 2 years after doxy-PEP was introduced.
The antibiotic, which was recently approved for treatment of urinary tract infections, was found to be noninferior to the standard gonorrhea treatment.
A study of 40 female sex workers reveals that a single daily dose of doxycycline is associated with significantly reduced STIs, primarily syphilis.
The at-home test can detect chlamydia, gonorrhea, and trichomoniasis and deliver results within 30 minutes.
Researchers found that roughly 30% of chlamydia and gonorrhea patients did not receive treatment, while only 14% and 39% received recommended antibiotics.
Researchers found "exceedingly high" levels of gonococcal tetracycline resistance in 8 African and Asian countries.
Researchers find a marked increase in tetracycline-resistant gonorrhea and increased colonization with tetracycline-resistant Staphylococcus aureus following the rollout of doxyPEP.
